Novo Nordisk announces more than 400 million euro expansion in its manufacturing facility in Athlone, Ireland

Summary by AI BETAClose X

Novo Nordisk is investing 432 million euro in its Athlone, Ireland manufacturing facility to significantly expand production capacity for current and future GLP-1 treatments, particularly oral products. This strategic expansion will enhance supply for markets outside the US and is expected to create up to 500 construction jobs, with project completion anticipated between the end of 2027 and 2028.

Disclaimer*

UK 100

Latest directors dealings